Core Points - Zevra Therapeutics, Inc. announced the re-election of Wendy L. Dixon, Ph.D. and Tamara A. Favorito to its Board of Directors, serving until the 2028 Annual Meeting [1][2] - The Board expressed gratitude for stockholder participation and support, viewing the election results as a validation of their strategic direction and progress over the past two years [2][4] - Daniel J. Mangless attempted to nominate alternative candidates but failed to meet SEC proxy rules and the Company's bylaws, resulting in his nominations being disregarded [2][3] Company Strategy and Performance - The Board and management reaffirmed their commitment to driving growth and executing their strategic plan, focusing on creating long-term value for stockholders [2][4] - The election results indicated strong stockholder support for the Board's industry expertise and commitment to delivering value [4] Financial Oversight - Stockholders approved the appointment of Ernst & Young LLP as the independent auditors for the fiscal year ending December 31, 2025 [5] Company Overview - Zevra Therapeutics is a commercial-stage company dedicated to developing therapies for rare diseases, utilizing data-driven strategies to overcome drug development challenges [6]